N-glycosylation of plant-produced recombinant proteins
- PMID: 23394562
- DOI: 10.2174/1381612811319310006
N-glycosylation of plant-produced recombinant proteins
Abstract
Plants are gaining increasingly acceptance as a production platform for recombinant proteins. One reason for this is their ability to carry out posttranslational protein modifications in a similar if not identical way as mammalian cells. The capability of plants to carry out human-like complex glycosylation is well known. Moreover, the targeted manipulation of the plant N-glycosylation pathway allows the production of proteins carrying largely homogeneous, human-type oligosaccharides. These outstanding results have placed plants in a favourable position compared to other eukaryotic expression systems. This review provides a comprehensive summary of the N-glycosylation of plant-produced recombinant proteins, the possible impact of plant-specific N-glycans on the human immune system, and recent advances in engineering the plant N-glycosylation pathway towards the synthesis of (complex) human-type glycan structures, highlighting challenges and achievements in the application of these powerful technologies.
Similar articles
-
Glyco-engineering in plants to produce human-like N-glycan structures.Biotechnol J. 2012 Sep;7(9):1088-98. doi: 10.1002/biot.201200032. Epub 2012 Aug 14. Biotechnol J. 2012. PMID: 22890723 Review.
-
Improving Protein Quantity and Quality-The Next Level of Plant Molecular Farming.Int J Mol Sci. 2022 Jan 25;23(3):1326. doi: 10.3390/ijms23031326. Int J Mol Sci. 2022. PMID: 35163249 Free PMC article. Review.
-
Controlled glycosylation of plant-produced recombinant proteins.Curr Opin Biotechnol. 2014 Dec;30:95-100. doi: 10.1016/j.copbio.2014.06.008. Epub 2014 Jul 5. Curr Opin Biotechnol. 2014. PMID: 25000187 Review.
-
N-glycosylation of recombinant pharmaceutical glycoproteins produced in transgenic plants: towards an humanisation of plant N-glycans.Curr Pharm Biotechnol. 2000 Dec;1(4):347-54. doi: 10.2174/1389201003378843. Curr Pharm Biotechnol. 2000. PMID: 11467331 Review.
-
Glyco-engineering of moss lacking plant-specific sugar residues.Plant Biol (Stuttg). 2005 May;7(3):292-9. doi: 10.1055/s-2005-837653. Plant Biol (Stuttg). 2005. PMID: 15912449
Cited by
-
Plant-Produced Monoclonal Antibody as Immunotherapy for Cancer.Biomed Res Int. 2020 Aug 24;2020:3038564. doi: 10.1155/2020/3038564. eCollection 2020. Biomed Res Int. 2020. PMID: 32908881 Free PMC article. Review.
-
Glycan structure and serum half-life of recombinant CTLA4Ig, an immunosuppressive agent, expressed in suspension-cultured rice cells with coexpression of human β1,4-galactosyltransferase and human CTLA4Ig.Glycoconj J. 2015 May;32(3-4):161-72. doi: 10.1007/s10719-015-9590-x. Epub 2015 May 14. Glycoconj J. 2015. PMID: 25971702
-
Plant specific N-glycans do not have proven adverse effects in humans.Nat Biotechnol. 2016 Jul 12;34(7):706-8. doi: 10.1038/nbt.3556. Nat Biotechnol. 2016. PMID: 27404878 No abstract available.
-
Generation and analysis of novel plant-derived antibody-based therapeutic molecules against West Nile virus.PLoS One. 2014 Mar 27;9(3):e93541. doi: 10.1371/journal.pone.0093541. eCollection 2014. PLoS One. 2014. PMID: 24675995 Free PMC article.
-
β1,3-galactosyltransferase on chromosome 6 is essential for the formation of Lewis a structure on N-glycan in Oryza sativa.Transgenic Res. 2023 Oct;32(5):487-496. doi: 10.1007/s11248-023-00360-y. Epub 2023 Aug 4. Transgenic Res. 2023. PMID: 37540410
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources